In conclusion, the MDK-NCL signaling network may influence cervical cancer by impacting the immune microenvironment and promoting the malignant phenotype of tumor cells, with NCL expression linked to immune suppression, while MDK remains a potential target for cervical cancer therapy. The gene discussed is NUCLEOLIN; the disease is neoplasm.